1 / 15

CAFE TRIAL

CAFE TRIAL. Ron Beasley, PharmD Candidate Preceptor: Soheyla M ahdavian, PharmD. CAFE TRIAL. C omparison of A typicals in F irst E pisode of p sychosis

mirra
Télécharger la présentation

CAFE TRIAL

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CAFE TRIAL Ron Beasley, PharmD Candidate Preceptor: SoheylaMahdavian, PharmD

  2. CAFE TRIAL • Comparison of Atypicals in First Episode of psychosis • The study, Comparison of Atypicals for First-Episode Psychosis (CAFE), involved 26 centers in the U.S. and Canada, and it recruited patients who were experiencing their first psychotic episode. • CAFE was funded by AstraZeneca, the maker of Seroquel. • Published in the American Journal of Psychiatry in 2007

  3. Objectives • To determine whether there were any advantages among the atypical antipsychotic agents for first-episode • This was a 52-week randomized, double-blind, flexible-dose, multicenter study

  4. Methods • Compared quetiapine (Seroquel®), risperidone (Risperdal®), and olanzapine (Zyprexa®) in these patients. • There were 134 patients in the quetiapine (Seroquel®) group and 133 each in the olanzapine and risperidone(Risperdal®) groups.

  5. Criteria Inclusion Exclusion The patients could not have had a previous psychotic episode from which they recovered; nor could they have a lifetime history of more than 16 weeks of antipsychotic treatment. • 16 to 40 years old, had a diagnosis of first-episode schizophrenia, and had psychotic symptoms for one month to five years, • Scores greater than 4 on the Positive and Negative Symptoms Score (PANSS) psychosis subscale.

  6. Positive and Negative Syndrome Scale • The PANSS or the Positive and Negative Syndrome Scale is a medical scale used for measuring symptom severity of patients with schizophrenia. • 1-Absent • 2-Minimal • 3-Mild • 4-Moderate • 5-Moderate severe • 6-Severe • 7-Extreme

  7. Positive Scale • 7 Items, (minimum score = 7, maximum score = 49) • Delusions • Conceptual disorganization • Hallucinations • Hyperactivity • Grandiosity • Suspiciousness/persecution • Hostility

  8. Negative Scale • 7 Items, (minimum score = 7, maximum score = 49) • Blunted Affect • Emotional withdrawal • Poor rapport • Passive/apathetic • Difficulty in abstract thinking • Lack of spontaneity and flow of conversation • Stereotyped thinking

  9. General Psychopathology Scale • 16 Items, (minimum score = 16, maximum score = 112) • Somatic concern • Anxiety • Guilt feelings • Tension • Mannerisms and posturing • Depression • Motor retardation • Uncooperativeness • Unusual thought content • Disorientation • Poor attention • Lack of judgment and insight • Disturbance of volition • Poor impulse control • Preoccupation • Active social avoidance

  10. PANSS Total Score • Minimum = 30 • Maximum = 210 • The PANSS is a relatively brief interview, requiring 45 to 50 minutes to administer.

  11. Primary Outcome Measurment • Discontinuation of treatment could be due to an • Inadequate effect • Adverse effects • Patient decision • Failure to keep appointments, • Desire to stop medication for personal reasons • Patient-specific reasons for stopping treatment. • The average doses were 11.7 mg for olanzapine, 506 mg for quetiapine, and 2.4 mg for risperidone.


  12. Results • There was no difference among the drugs in terms of the all-cause discontinuation rate • After one year of treatment, all three of the medications had a pretty high rate of discontinuation, about 70% in all of them. • There was no difference in subcategories of reasons for discontinuation, whether it was patient decision or inadequate effect • The analysis of the improvement of positive symptoms showed that patients on olanzapine improved more than those on quetiapine

  13. Results Cont. • Of those treated with olanzapine, 80% gained 7% or more over their baseline weight compared with 57.6% of those receiving risperidone and 50% of those receiving quetiapine.

  14. Critique Pros Cons They allowed patients who had some prior antipsychotic treatment to participate CAFE was funded by AstraZeneca, the maker of Seroquel. • The three testing groups were not significantly different giving more accurate results • They tested for multiple secondary outcomes making this trial more clinically useful

  15. References • 1. Gaebel W, Moller HJ, Buchkremer G, Ohmann C, Riesbeck M, Wolwer W, Von Wilmsdorff M, Bottlender R, Klingberg S: Phar- macological long-term treatment strategies in first episode schizophrenia: study design and preliminary results of an on- going RCT within the German Research Network on Schizo- phrenia. Eur Arch Psychiatry Clin Neurosci 2004; 254:129–140 • 2. Good KP, Kiss I, Buiteman C, Woodley H, Rui Q, Whitehorn D, Kopala L: Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis. Br J Psychiatry 2002; 43(suppl):S45–S49 • 3. MallaAK, Norman RM, Scholten DJ, Zirul S, Kotteda V: A com- parison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. J Clin Psychiatry 2001; 62:179–184

More Related